Bridge Biotherapeutics Launches a Research Collaboration with Emory University School of Medicine to Explore Combination Therapy of BBT-877 for KRAS/P53 Mutant NSCLC Patients Resistant to Anti-PD-1 Blockade ...Middle East

SEONGNAM, South Korea and ATLANTA, March 28, 2024 /PRNewswire/ -- Bridge Biotherapeutics (KQ288330), a South Korean clinical-stage biotech company developing novel drugs for cancer, fibrosis, and inflammation, announced a research collaboration with Dr. Jessica M. Konen's Lab at Emory...

Hence then, the article about bridge biotherapeutics launches a research collaboration with emory university school of medicine to explore combination therapy of bbt 877 for kras p53 mutant nsclc patients resistant to anti pd 1 blockade was published today ( Friday 29/03/2024 - 01:12 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Bridge Biotherapeutics Launches a Research Collaboration with Emory University School of Medicine to Explore Combination Therapy of BBT-877 for KRAS/P53 Mutant NSCLC Patients Resistant to Anti-PD-1 Blockade )

Also on site :

• Saks Global Secures $1.75 Billion of Committed Capital and Announces Return of Industry Veterans to Advance Transformation of Iconic Luxury Portfolio
• Another Weight Loss Surgery and a Wedding Bombshell: Spoilers From '1000-Lb Sisters' Season 8 Episode 2
• Trump-Iran latest: President threatens ‘very strong action’ if protesters are hanged after forced confessions